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In this manuscript, we report the development of a versatile,
robust, and stable targeting nanocarrier for active delivery. This
nanocarrier is based on bifunctionalized polymeric nanoparticles
conjugated to a monoclonal antibody that allows for active target-
ing of either (i) a fluorophore for tracking or (ii) a drug for monitor-
ing specific cell responses. This nanodevice can efficiently dis-
criminate between cells in coculture based on the expression
levels of cell surface receptors. As a proof of concept, we have
demonstrated efficient delivery using a broadly established cell
surface receptor as the target, the epidermal growth factor recep-
tor (EGFR), which is overexpressed in several types of cancers.
Additionally, a second validation of this nanodevice was success-
fully carried out using another cell surface receptor as the target,
the cluster of differentiation 147 (CD147). Our results suggest that
this versatile nanocarrier can be expanded to other cell receptors
and bioactive cargoes, offering remarkable discrimination
efficiency between cells with different expression levels of a
specific marker. This work supports the ability of nanoplatforms to
boost and improve the progress towards personalized medicine.
Introduction
Standard anti-cancer therapies use cytotoxic agents that target
proliferative (malignant and non-malignant) cells. However,
despite the improved efficacy and enhanced survival offered by
these chemotherapies, there are still many side effects linked
to the lack of specific delivery to tumor cells. Therefore, there
is a real clinical demand for targeted approaches to improve
patient outcomes. Cellular surface receptors play a fundamen-
tal role in the progression of various diseases, including
cancer. In fact, cancer cells overexpress numerous surface
receptors that become important targets for the diagnosis and
treatment of cancer.1–3 Depending on the level of expression of
a specific receptor, cancer cells can respond with different
efficacy to a particular treatment. Building a cost-effective and
versatile nanodevice, which carries out targeted delivery of a
particular treatment depending on the level of expression of a
specific receptor, can have a relevant impact on the develop-
ment of personalized medicine.4–7 Currently, several
approaches aimed at achieving targeted delivery based on
nanotechnology are in development.8,9 In particular, targeted
nanoparticles as vehicles for the release of drugs and bio-
molecules to cancer cells that overexpress a particular cell
surface receptor have been widely used.10–12 One of the most
popular strategies to achieve active targeting is inspired by the
antibody–drug conjugates (ADCs), which have delivered five
FDA-approved compounds to the market.13 The conjugation of
a monoclonal antibody to nanoparticles (Ab-NPs) allows for
the targeting of specific antigens overexpressed in tumor cells
and other cells present in the tumor microenvironment. This
approach provides a successful means to deliver cytotoxic treat-
ments to specific cancer types.14–16
We have previously reported the use of cross-linked poly-
styrene-based nanoparticles for the efficient conjugation of
bioactive molecules of different nature such as small drugs,
sensors, proteins, and nucleic acids. These polystyrene nano-
particles have been implemented for imaging, biosensing,
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tracking of cellular proliferation, metallofluorescent nano-
particles for multimodal applications, and in cellulo proteo-
mics using drug-loaded fluorescent nanoparticles.17–19 These
polymeric particles are inherently attractive as a delivery
system because of certain advantages, such as being easy to
handle, and robust with a defined drug loading capacity, tun-
ability, and lack of toxicity. These nanosystems can achieve
efficient delivery through a passive but rapid mechanism,
without significant alterations involving cellular gene profiling
or proteomics.20,21 Recently, a theranostic multifunctional
nanodevice for breast cancer treatment and monitoring was
successfully developed.22 Based on the results of the previous
studies, we hypothesized that active targeting for selective
drug delivery applications could be efficiently achieved using
these polymeric nanoparticles.
Here, we propose the development of a robust and stable
targeting nanocarrier for active delivery based on bifunctiona-
lized polymeric nanoparticles (NPs) conjugated to a mono-
clonal antibody (Ab). This nanodevice allows for active target-
ing of either (i) a fluorophore for active tracking or (ii) a drug
for monitoring specific cell responses depending on the
expression levels of surface proteins. This approach has been
successfully validated using two different antibodies that
specifically recognize two receptors commonly overexpressed
on the cell surface of several types of tumors, the epidermal
growth factor receptor (EGFR)23 and the cluster of differen-
tiation 147 (CD147),24,25 and that have been involved in cancer
progression and poor prognosis. Additionally, we demonstrate
the robust implementation of this nanodevice in cocultures
for evaluating the efficacy of cell internalization based on the
levels of these receptors. Therefore, we propose an effective
polymeric nanocarrier that specifically recognizes tumor-
specific cell surface markers and can potentially target tumor
cells without affecting normal tissues. This feasible and versa-
tile conjugation protocol is broadly applicable and can be
applied to other drug cargoes or tumor markers, demonstrat-




We selected commonly overexpressed surface markers in
tumors based on gene expression profiles across diverse
human cancer and normal tissues to develop the targeted
nanodevice.26 Here, we identified EGFR as a potential cell
surface receptor, which is overexpressed among several types
of cancers (Fig. S1a, see ESI†). Next, a strategy to couple a
specific antibody to polymeric NPs for targeting delivery,
together with (i) a fluorophore to allow cell tracking (Fig. 1, top
panel) or (ii) an FDA-approved antitumoral drug (Fig. 1,
bottom panel) was designed. These nanoparticles were pre-
pared following standard and easy to handle protocols based
on Fmoc solid-phase chemistry with oxyma and N,N′-diiso-
propylcarbodiimide (DIC) as coupling reagents (see synthetic
details in Scheme S1†). The core scaffold for this nanoformula-
tion is a nanoparticle bifunctionalized, NH2-BCN-NPs (5), that
Fig. 1 Schematic illustration for the synthesis of bifunctional-targeted nanoparticles (Ab-NPs and Ab-DOX-NPs).
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contains a free amino group for further conjugation of the
desired bioactive cargo, a fluorophore or a drug, and a cyclooc-
tyne moiety (BCN), for further conjugation of the selected anti-
body to achieve targeted delivery. BCN allows for copper-free
1,3-cycloadditions with azide-labeled biomolecules in aqueous
conditions (see synthetic details Scheme S1, ESI†).27 These
NH2-BCN-NPs (5) were obtained from amino-functionalized
cross-linked polystyrene nanoparticles (Naked-NPs (1) by (i)
PEGylation (to improve their biocompatibility), (ii) conjugation
of orthogonally-protected lysine (Fmoc-Lysine(Dde)-OH) to
achieve bifunctionalization,28 and (iii) BCN functionalization
of one of the arms of the lysine scaffold by reacting its NHS-
activated ester (BCN-NHS) (details in Scheme S2, see ESI†).
Different synthetic routes can be utilized following amine de-
protection of the second arm from NH2-BCN-NPs (5), depend-
ing on the bioactive cargo to be delivered. To obtain fluo-
rescent-labeled NPs, BCN-NPs (6), a standard conjugation of
the fluorophore via amide formation was carried out using car-
boxyfluorescein (CBF) or Cy5 to obtain F-BCN-NPs (6A) or Cy5-
BCN-NPs (6B), respectively. Conversely, to obtain drug-loaded
NPs, DOX-BCN-NPs (10), doxorubicin was conjugated by hydra-
zone bond formation (which allows for pH-selective delivery in
the future).29 Once the desired bioactive cargo was loaded onto
the nanoparticle, a final step for decoration of the NPs with
the antibody was efficiently carried out following an efficient
one-step click chemistry approach in aqueous conditions, in
particular a 1,3-cycloaddition. Thus, the azide functionalized
antibody (Ab-N3) was conjugated to the NP by the BCN moiety
to yield Ab-loaded nanoparticles. A set of nanoparticles to
target EGFR (EGFR-F-NPs (7A-1), EGFR-Cy5-NPs (7B-1), and
EGFR-DOX-NPs (11-1) and a second set of nanoparticles to
target an irrelevant antibody, IgG1 (IgG1-F-NPs (7A-3), IgG1-
Cy5-NPs (7B-3), and Ig-G1-DOX-NPs (11-3) were prepared using
this designed protocol (Fig. 1, Schemes S1 and S3, see ESI†)
proving the reproducibility of the protocol. While different
combinations of antibodies with fluorophore and drug have
been conjugated to validate the process, other small molecules
and bioactive cargoes could be conjugated following similar
chemical strategies, which demonstrates the versatility of this
nanoformulation.
Characterization of Ab-NPs
A full characterization of the obtained nanoformulations was
performed. Fig. 2 shows the data obtained for EGFR-F-NPs
(7A-1) and EGFR-DOX-NPs (11-1) and their chemical structure
(Fig. 2a). Size distribution was determined by Dynamic Light
Scattering (DLS), showing the homogeneous size and low poly-
dispersity (Fig. 2b). Transmission microscopy images show a
smooth surface without any aggregation of EGFR-NPs and cor-
roborate their size (insets in Fig. 2b). Fig. 2c shows the zeta
potential values in aqueous environments at pH 7.4, which
shows negative values of NPs. These results also confirm the
ability of zeta potential measurements to monitor chemical
reactions performed on NPs.30 The concentration of NPs was
calculated according to the method developed by our research
group, and it was found to be 2.2 × 106 nanoparticles per mL
(Fig. S11, see calculation details in ESI†).31 Next, the efficacy of
conjugation of the antibody was checked by (i) immunofluor-
escence and (ii) gel electrophoresis using Coomassie staining
performed on anti-EGFR-conjugated NPs (7A-1 and 11-1),
using nanoparticles without antibody, F-BCN-NPs (6A) and
DOX-BCN-NPs (10) as negative controls. The results qualitat-
ively confirmed the presence of the antibody conjugated to
NPs (Fig. 2d and e). Then, the conjugation efficiency and
loading capacity (LC) of the antibody and biocargo on the NPs
were determined (Fig. 2f, Fig. S12, S13 and Table S3, and
details of the calculations of these parameters are available in
the ESI†). As expected, the number of molecules of anti-EGFR
per nanoparticle was lower than the number of small mole-
cules. We hypothesized that this resulted from the larger size
of the antibody compared with the size of the fluorophores or
the drug. The efficient conjugation of these bioactive cargoes
was corroborated by flow cytometry (Fig. S2, see ESI†). The
efficiency of the pH-sensitive release of DOX from
EGFR-DOX-NPs (11-1) was also determined (Fig. S14, see ESI†).
Additionally, the characterization of EGFR-Cy5-NPs (7B-1) was
carried out, showing effective conjugations (Fig. S3, see ESI†).
Evaluation of specific nanofection capacity
To validate the efficacy of EGFR-F-NPs (7A-1) for active target-
ing, the nanofection capacity was evaluated by testing EGFR-F-
NP (7A-1) internalization in lung cancer cells expressing
different levels of EGFR. After quantifying gene expression,
two lung cancer cell lines were selected: A549 with high-level
expression of EGFR (EGFR high), and H520 with low levels of
EGFR expression (EGFR low) (see qPCR analysis of EGFR in
A549 and H520 in Fig. S15a, see ESI†). Nanoparticles without a
conjugated antibody (F-BCN-NPs (6A)) together with nano-
particles conjugated with a nonspecific antibody of the same
isotype, IgG1 (IgG1-F-NPs (7A-3)) were used as negative con-
trols (details of the preparation of 7A-3 NPs are available in
section 4 of ESI†). The nanofection efficiency was evaluated
using flow cytometry (Fig. 3b and c). As expected, a greater
internalization of EGFR-F-NPs (7A-1) was observed in the A549
cells compared with the H520 cells. Notably, the nanofection
capacity of EGFR-F-NPs (7A-1) increased when EGFR levels
were increased, while the nanofection capacity of the control
IgG1-F-NPs (7A-3) remained constant in both cases. Therefore,
cell internalization of EGFR-F-NPs (7A-1) is significantly
dependent on EGFR expression levels. Additionally, the relative
nanofection efficiency of EGFR-F-NPs (7A-1) compared with
NPs without antibody (F-BCN-NPs (6A)) reinforces the fact that
the internalization of these NPs is directly related to the pres-
ence of the surface receptor (Fig. 3c). In order to prove cell
internalization, different time points of nanofection were
tested (Fig. S4, see ESI†). An increase of fluorescence intensity
over time was observed indicating that the efficient internalis-
ation of these nanoparticles was achieved. Based on these
results, 1.5 hours was chosen as the optimal incubation time.
Efficient internalization was further corroborated by confocal
microscopy analysis, where we demonstrated intracellular
EGFR-F-NP (7A-1) internalization in the high EGFR expression
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cell line (A549) (Fig. 3d and e). Additionally, the evaluation of
cellular uptake of EGFR-loaded nanoparticles labeled with Cy5
instead of CBF (EGFR-Cy5-NPs (7B-1)) was also successfully
carried out, showing the same qualitative results (Fig. S5, see
ESI†). Fig. 3f shows EGFR trafficking through endosomal/lyso-
somal compartments for the internalization of EGFR-F-NPs
(7A-1) upon binding of active NPs to the receptor. This result is
in accordance with the previously reported EGFR-mediated
internalization process.32
To further verify the specificity of the EGFR-F-NP (7A-1)
internalization resulting from targeting of the EGFR, competi-
tive binding experiments were performed. To that end, cells
were preincubated in the presence of the free EGFR antibody
before incubation with the antibody-loaded NPs, EGFR-F-NPs
(7A-1), F-BCN-NPs (6A), and IgG1-F-NPs (7A-3) as negative con-
trols (EGFR + bars, Fig. 3g). In parallel, a negative control
where cells were incubated with the set of nanoparticles
without EGFR pretreatment in solution was carried out (EGFR
− bars, Fig. 3g). These results showed that pretreating cells
with the antibody (EGFR+) effectively blocked cell-binding
sites preventing the recognition of epitopes from the nano-
devices and significantly reducing EGFR-F-NPs (7A-1) uptake.
Cellular internalization of EGFR-F-NPs (7A-1) in A549 (EGFR
high) with the preincubated anti-EGFR antibody was signifi-
cantly reduced to values slightly higher than the controls
(F-BCN-NPs (6A) and IgG1-F-NPs (7A-3)). In contrast, the
degree of internalization of these control nanoparticles
remained constant despite preincubation with the antibody
(Fig. 3g). Therefore, these results confirm that the nanofection
of EGFR-F-NPs (7A-1) resulted from specific receptor-mediated
binding. This finding validated the ability of EGFR-F-NPs
(7A-1) to discriminate between cells with different receptor
expression levels and showed their potential for use in active
targeting. Additionally, we wanted to monitor whether the
internalization of EGFR-F-NPs (7A-1) impacted cell viability
using the resazurin assay. To that end, cells were incubated for
72 h with different concentrations of EGFR-F-NPs (7A-1) and
control NPs (maximum concentration = 40 000 NPs per cell).
Fig. 2 Characterization of EGFR-F-NPs (7A-1) and EGFR-DOX-NPs (11-1). (a) Schematic representation of NPs; (b) hydrodynamic diameter values of
DLS and TEM image; (c) zeta potential value; (d) immunofluorescence of EGFR-F-NPs (7A-1) and EGFR-DOX-NPs (11-1) versus F-BCN-NPs (6A) and
DOX-BCN-NPs (10) respectively; (e) coomassie staining of electrophoresis gel; (f ) determination of conjugation efficiency and loading capacity of
anti-EGFR and F/DOX per nanoparticle.
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Our results showed that cell viability values above 95% in all
the cases tested, corroborating that high NPs per cell concen-
trations do not affect cell viability (Fig. S6, see ESI†).
Evaluation of EGFR-NPs as active targeting nanocarriers using
a cell coculturing approach
After demonstrating the efficacy of this nanoplatform to dis-
criminate between cells with high and low expression of
surface receptors, we sought to assess its efficiency for active
targeting using a coculturing approach. For this purpose, an
in vitro A549/H520 coculture model was used to evaluate
selectivity and active targeting of EGFR-F-NPs (7A-1). H520
cells were pre-stained with CellTracker™ Deep Red to be able
to track them and then cocultured in vitro at different ratios of
A549 cells (EGFR high)/H520 cells (EGFR low) (10% : 90%,
25% : 75%, 50% : 50%, and 75% : 25%). Cocultures were incu-
bated with EGFR-F-NPs (7A-1) at a concentration of 5000
added NPs per cell for 90 min and analyzed by flow cytometry
(Fig. 4a). A correlation between the ratio of CellTracker™ label-
ing of H520 and EGFR-F-NPs (7A-1) nanofection of A549 cells
was established. These results show that uptake of EGFR-F-
NPs (7A-1) is specific for EGFR in a coculture model, highlight-
Fig. 3 Selective nanofection and viability assays of EGFR-F-NPs (7A-1). The A549 and H520 cell lines were incubated with 5000 NPs per cell for
1.5 h in nanofection experiments and the results were analyzed using flow cytometry; (a) schematic representation of NPs; (b) comparison of the
efficacy of nanofection of EGFR-F-NPs (7A-1) against the controls used; (c) uptake of EGFR-F-NPs (7A-1) related to F-BCN-NPs (6A); (d) confocal
microscopy of the cellular uptake behavior of EGFR-NPs (7A-1); (e) orthogonal view (xy, xz, and yz) of the confocal microscope images showing the
intersection planes at the position of the cross-line. Maximum intensity projection of the z-stack from blue (DAPI, nuclei), red (CellTracker™ Deep
Red, cytoplasm) and green (EGFR-F-NPs (7A-1)) in A549 cell line is displayed; (f ) confocal images of the co-localization study of EGFR-F-NPs (7A-1)
with lysosomes (top) employing Lysotracker Red and with late endosomes (bottom) using antiCD63 primary antibody followed by A647-secondary
antibody for late endosomes staining in A549 cell line. Lysosomes or late endosomes (red), and EGFR-F-NPs (7A-1) (green) can be seen co-localized
(orange) after 1.5 h of incubation. Nuclei (blue) were stained with DAPI; (g) competitive binding assay. Comparison of cellular nanofection between
EGFR-F-NPs (7A-1) and F-BCN-NPs (6A) and IgG1-F-NPs (7A-3) as negative controls. 5000 NPs per cell were incubated with (EGFR+) and without
(EGFR−) the presence of free anti-EGFR (2.5 µm). The experiments have been carried out in triplicate and the results have been expressed with the
values of the mean ± SEM. The statistical significance was determined by the Student’s T-test (*p-value < 0.05, ****p-value < 0.0001).
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ing the potential use of EGFR-F-NPs (7A-1) (Fig. 4b).
Additionally, this result was corroborated by confocal
microscopy analysis (Fig. 4c). As expected, the cellular internal-
ization of EGFR-labeled nanoparticles (indicated as green
dots) inside H520 cells labeled with cell membrane staining
(EGFR low) is significantly lower than inside A549 cells (EGFR
high). Remarkably, when the same experiment was carried out
with EGFR-labeled NPs loaded with doxorubicin (Fig. 4c), the
correlation between the proportion of internalization was kept
the same as that with NPs loaded with the fluorophore. These
results reinforce the reproducibility and reliability of this
nanoplatform, as two different formulations, EGFR-DOX-NPs
(11-1) and EGFR-F-NPs (7A-1), showed the same ratio of intern-
alization (%) based on EGFR expression levels. Previous results
of active targeting nanocarriers based on the encapsulation of
the bioactive cargo in a co-culture system have been reported.33
Alternatively, our approach leads the covalent conjugation of
the bioactive cargo allowing efficient co-culture evaluation in
shorter incubation time.
Evaluation of EGFR-DOX-NPs (11-1) efficacy as drug delivery
nanocarrier
We evaluated the ability of EGFR-DOX-NPs (11-1) as selective
drug delivery nanocarriers. First, the cytotoxic activity of
EGFR-DOX-NPs (11-1) was evaluated by measuring cell viabi-
lity of both A549 (EGFR high) and H520 (EGFR low) cells,
incubated with a range of concentrations of NPs, using the
resazurin cell viability assay. The IC50 of EGFR-DOX-NPs (11-
1) was calculated to be 58.6 nM for A549 cells and 156 nM for
the H520 cell line. Therefore, EGFR-DOX-NPs (11-1) had
approximately three times lower IC50 values for A549 when
compared with H520 cells (Fig. 5a), showing the robustness
of active targeting in improving the drug anti-proliferative
capacity (Fig. S7†). When we compared the cytotoxic activity
of free DOX using an equivalent amount to those loaded on
EGFR-DOX-NPs (11-1) and IgG1-DOX-NPs (11-3), a similar
cytotoxic effect is observed between DOX-loaded onto nano-
particles and the same doses of free DOX in the A549 cell
line (EGFR high), whereas IgG1-DOX-NPs (11-3) show no cell
damage. The lower internalization of IgG1-DOX-NPs (11-3)
shows that there is a specific receptor mediated internaliz-
ation of EGFR-DOX-NPs (11-1). However, while free DOX also
reduced the cell viability of the H520 cell line, the effect of
EGFR-DOX-NPs (11-1) was more moderate because of their
lower cellular uptake as a direct consequence of the lower
presence of EGFR on the cell surface (Fig. 5b). Finally, to cor-
roborate the selective therapeutic effect of EGFR-DOX-NPs
(11-1), H520 and A549 were cocultured and treated with these
NPs for 1.5, 24, and 120 h. Confocal microscopy analysis
revealed how the proportion of A549 cells loaded with nano-
particles was similar to the proportion of H520 cells at 1.5 h
and 24 h. However, following 120 h of treatment, the cytotoxic
effect can be clearly observed as the number of cells loaded
with a high number of nanoparticles dramatically decreases
and the number of cells without nanoparticles increases
(Fig. 5c).
Fig. 4 EGFR-F-NP (7A-1) and EGFR-DOX-NP (11-1) efficacy in coculture. (a) Schematic illustration of the A549 (EGFR high) and H520 (EGFR low)
coculture model; (b) relative efficiency of nanofection in coculture of EGFR-F-NPs (7A-1) and EGFR-DOX-NPs (11-1) by flow cytometry analysis; (c)
confocal microscope images of cocultures with NPs.
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Doxorubicin is a genotoxic drug that can be related to the
histone variant H2A·X phosphorylation in response to the
damage of DNA. Therefore, we decided to comprehensively
study the cytotoxic effect and the selectivity conferred by the
antibody on EGFR-DOX-NPs (11-1) by measuring the level of
DNA damage by γ-H2Ax staining. Active targeting would lead
to a significant accumulation of DOX in the high EGFR cell
line (A549), which would be translated into an increased level
of DNA damage. For that purpose, cells were stained with anti-
phospho-H2A·X antibody to visualize DNA damage by confocal
microscopy analysis (Fig. 5d and e). Then, the number of
H2A·X foci were used to quantify DNA damage (Fig. 5e).34–36
Based on the fact that a higher number of H2A·X foci per
nuclei are observed in A549 compared with H520 cells, we con-
firmed that nanofection of EGFR-DOX-NP (11-1) induced more
damage in A549 compared with H520 cells. When A549 and
H520 cells were incubated with NPs without the conjugated
antibody (DOX-BCN-NP (10)), a similar number of H2A·X foci
per nuclei were observed in both cell lines, but this value was
lower than what was achieved by active targeting with
EGFR-DOX-NP (11-1) (Fig. 5e).37 This result reinforces the
remarkable selectivity for drug delivery of this nanocarrier
EGFR-DOX-NP (11-1) to cells that overexpress EGFR on the cell
surface.
Fig. 5 Therapeutic evaluation of EGFR-DOX-NPs (11-1) on A549 (EGFR high)/H520 (EGFR low) cells. (a) Dose–response curves (percentage of cell
viability versus concentration) of treatment with EGFR-DOX-NPs (11-1), represented in nM; (b) therapeutic effect of EGFR-DOX-NPs (11-1) compared
with the corresponding concentration of free doxorubicin (500 nM) and IgG1-DOX-NPs (11-3) as negative control. Statistical significance was deter-
mined by Student’s t-test (*p value < 0.0001). (c) Confocal microscopy results of coculture (50 : 50) following 1.5, 24, and 120 h of treatment with
EGFR-DOX NPs (11-1); (d) determination of DNA damage caused by treatment with EGFR-DOX-NPs (11-1) by immunostaining of γ-H2Ax analyzed
by confocal microcopy (63x magnification). Blue, DAPI for the nucleus staining; red, EGFR-DOX-NPs (11-1) and green, for H2Ax staining with
Alexa488-antiphospho-H2Ax; (e) quantitative analysis of the number of foci per cell by H2AX staining following treatment with EGFR-DOX-NPs (11-
1) compared with DOX-BCN-NPs (10).
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Validation of the nanocarrier versatility for active targeting –
evaluation of NPs to tag the CD147 receptor
To further validate the versatility of this nanocarrier for targeted
delivery, a different cell surface receptor was selected as the
target, the cluster of differentiation 147 (CD147). CD147
is upregulated in various tumors, including breast, bladder, col-
orectal, ovarian cancer, melanoma, and osteosarcoma (Fig. S1b,
see ESI†). The antibody CD147 has been reported to be involved
in cancer progression and lactate metabolism and is also a
useful therapeutic target for malignant tumor cells.38–40
Nanoparticles labeled with the antiCD147 antibody were pre-
pared following the same protocols previously described for
nanoparticles labeled with the antiEGFR antibody (Fig. 1).
CD147-Cy5-NPs (7B-2) and CD147-DOX-NPs (11-2) (Fig. 6a) were
successfully synthesized and characterized (see Scheme S2 and
Fig. S8,† respectively). To carry out the in vitro evaluation of this
specific nanocarrier decorated with the antiCD147 moiety, four
established cell lines based on CD147 expression levels were
selected: two bone cancer cell lines classified as high CD147
(143B and ρ0206), one breast cancer cell line with lower levels of
expression of CD147 (MCF-7), and immortalized mouse embryo-
nic fibroblast (MEF) as an absolute negative control because the
selected anti-CD147 antibody only recognizes the human
epitope of the CD147 protein. In line with the CD147 density on
the cell surface, there was a significant enhancement in the
uptake of cellular CD147-Cy5-NPs (7B-2) in 143B and ρ0206 cells
compared with MCF-7 and MEF (Fig. 6b and c, S9†). Not only
was the percentage of nanofected cells increased, but there was
also increased accumulation of CD147-Cy5-NPs (7B-2) pro-
Fig. 6 Selective nanofection and viability assays of CD147-Cy5-NPs (7B-2). The A549 and H520 cell lines were incubated with 5000 NPs per cell for
1.5 h to nanofection experiments and the results were analyzed by flow cytometry; (a) schematic representation of NPs; (b) comparison of the
efficacy of nanofection of CD147-Cy5-NPs (7B-2) against the controls used; (c) uptake of CD147-Cy5-NPs (7B-2) related to BCN-Cy5-NPs (6B); (d)
orthogonal view (xy, xz, and yz) of the confocal microscope images showing the intersection planes at the position of the cross-line. Maximum
intensity projection of the z-stack from blue (DAPI, nuclei) and green for CD147-Cy5-NPs (7B-2) in 143B and ρ0206 cells are displayed; (e) competi-
tive binding assay. Comparison of cellular nanofection between CD147-Cy5-NPs (7B-2), BCN-Cy5-NPs (6B), and IgG1-Cy5-NPs (7B-3) as negative
controls. 5000 NPs per cell were incubated with (CD147+) and without (CD147−) the presence of free anti-CD147 (2.5 µm). (f ) Therapeutic effect of
CD147-DOX-NPs (11-2) compared with the corresponding concentration of free doxorubicin (500 nM). Statistical significance was determined by
one-way analysis of variance (ANOVA) with a Bonferroni’s multiple comparison post-hoc (*p value < 0.05, ***p value < 0.001). The experiments have
been carried out in triplicate and the results have been expressed with the values of the mean ± SEM.
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portional to the CD147 expression. This change was reflected in
the increased median fluorescence intensity (MFI). However,
IgG1-Cy5-NP (7B-3) treatment did not cause a change in MFI
(Fig. 6b). Efficient internalization was further corroborated by
confocal microscopy analysis, where we demonstrated intra-
cellular CD147-Cy5-NPs (7B-2) internalization in the high
CD147 expression cell line (143B and ρ0206) (Fig. 6d).
Similar to EGFR-F-NPs (7A-1) or EGFR-Cy5-NPs (7B-1), the
uptake of CD147-Cy5-NPs (7B-2) by 143B and ρ0206 cells
(CD147 high) was significantly reduced after preincubation
with anti-CD147 to levels similar to those observed in Cy5-
BCN-NPs (6B) and IgG1-Cy5-NPs (7B-3) (Fig. 6e). Interestingly,
cellular uptake efficiency was maintained in cells with
minimal CD147 expression (MCF-7 and MEF).
As previously described for EGFR loaded NPs, evaluation of
fluorescent labelled CD147-Cy5-NPs (7B-2) has proven non-sig-
nificant effect on cell viability (Fig. S10, see ESI†). Additionally,
to further validate the efficiency of CD147-DOX-NPs (11-2)
based on cell type-specific targeting, 143B and ρ0206 cells
(CD147 high) and MCF-7 and MEF (CD147 low) cells were
treated with CD147-DOX-NPs (11-2). Similar results were
obtained using CD147-DOX-NPs (11-2), with the viability of
CD147 high cell lines significantly more affected than CD147
low cell lines (Fig. S11†). Remarkably, the correlation between
the proportion of Ab-DOX-NP internalization and CD147
expression remains constant compared with NPs loaded with
Ig1 (Fig. 6f).
Altogether, these results reinforce the reproducibility and
reliability of this nanoplatform, as three different formulations,
Ab-DOX-NPs (11) Ab-F-NPs (7A) and Ab-Cy5-NPs (7B), showed
the same percentage of internalization based on cell surface
markers levels. Considering the number of technological bar-
riers that need to be examined when developing more efficient
and cost-effective active targeting, our results suggest that this
approach can overcome the current challenges related to techni-
cal feasibility issues in the formulation and characterization of
nanocarriers. Current strategies used to formulate active target-
ing nanocarriers are based in the encapsulation of drugs and
trackers in the core of the NP while targeted delivery is achieve
by conjugating the antibody to the surface of the NP.41 Our
approach is reproducible between different formulations with
different cargoes, demonstrating the robustness and versatility
of the formulation of these Ab-targeted nanodevices.
Experimental section
Materials and methods
All solvents, chemicals, and monoclonal antibodies were pur-
chased from Sigma-Aldrich. Dulbecco’s modified Eagle’s
medium (DMEM), Roswell Park Memorial Institute medium
(RPMI), L-glutamine, 1% penicillin/streptomycin, trypsin-
EDTA, and fetal bovine serum (FBS) were purchased from
Gibco (Thermo Fisher Scientific). Flow cytometry experiments
were performed on a FACSCanto II system (Becton Dickinson &
Co., NJ, USA) using the Flowjo® 10 software for analysis. Cell
viability was assayed using an M200 Nanoquant microplate
reader to measure absorbance. Confocal microscopy images
were obtained using a Zeiss LSM 710 confocal laser scanning
microscope and Zeiss ZEN 2010 software for image acqui-
sition. Transmission electron microscopy was performed on
an FEI Titan G2 high-resolution microscope.
Preparation of Ab-NPs
Preparation of EGFR-F-NPs (7A-1) and CD147-Cy5-NPs (7B-2).
Bifunctionalized NPs (Fmoc-Dde-NPs, 4) were obtained using
protocols described previously (see ESI†).22 Next, the Fmoc
group was removed from Fmoc-Dde-NPs (4), and a solution
with 10 equivalents of cyclooctin BCN in anhydrous DMF with
1 equivalent of DIPEA was added, and the suspension was
mixed on the Thermomixer at 1400 rpm for 15 h at 25 °C.
Finally, Dde deprotection was carried out to yield NH2-
BCN-NPs (5).
Next, labeling of NPs was carried out by conjugation of 5(6)-
carboxyfluorescein (15 eq.) to obtain F-BCN-NPs (6A) (for conju-
gation of Cy5 see ESI†). The coupling of NPs with anti-EGFR
functionalized with azide group was optimized for 3 × 1010 NPs
(quantified by the spectrophotometric method, see ESI†)42 and
2.5 µM of antibody dissolved in PBS, and the suspension was
mixed on the Thermomixer at 1000 rpm for 12 h at 25 °C.
When the reaction concluded, the NPs were washed with sterile
PBS and EGFR-F-NPs (7A-1), EGFR-Cy5-NPs (7B-1), and CD147-
Cy5-NPs (7B-2). The IgG1 antibody was conjugated using the
same functionalization and conjugation process followed by the
anti-EGFR antibody to finally obtain the IgG1-F-NPs (7A-3) and
IgG1-Cy5-NPs (7B-3) (Schemes S1 and S2, see ESI†).
Preparation of Ab-DOX-NPs
First, the conjugation of succinic anhydride (15 eq.) with DIPEA
(7.5 eq.) was carried out to obtain COOH-BCN-NPs (8). Then,
the NPs (8) were activated with oxyma (15 eq.) and DIC (15 eq.)
for 4 h, centrifuged, and a solution of hydrazine in DMF (55%
v/v) was added. This was left stirring for 15 h at 25 °C. Next, the
Hydrazine-BCN-NPs (9) were washed and conditioned in 1 mL
of PBS pH 6. Then, DOX (1 equivalent) was dissolved in PBS at
pH 6 and added to the NPs, and the resulting mixture was
mixed for 15 h at 50 °C to yield DOX-BCN-NPs (10). Finally, the
conjugation of antibody with DOX-BCN-NPs (10) was carried
out to obtain EGFR-DOX-NPs (11-1), CD147-DOX-NPs (11-2),
and IgG1-DOX-NPs (11-3) (Scheme S4, see ESI†).
Functionalization of the antibody with N3-PEG4-NHS
To functionalize the antibody with N3-PEG4-NHS reagent, a
500 mM solution of N3-PEG4-NHS in PBS was prepared, where
1 mM stock solution (20× M excess) was added to 2.5 µM of
antibody. The reaction was incubated for 2 h at 4 °C and con-
centrated using 30 KDa MWCO purification columns following
the manufacturer’s specifications (Scheme S1b, see ESI†).
Characterization of Ab-NPs
Particle mean size, size distribution, and zeta potential of NPs
were determined by dynamic light scattering (DLS) and were
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measured on a Zetasizer Nano ZS ZEN. The shape and mor-
phology of the NPs were observed by transmission electron
microscopy (TEM). The conjugation of fluorophores was
checked by flow cytometry using FACSCanto II (Becton
Dickinson & Co.) and Flowjo® 10 software for data analysis.
The antibody conjugation efficiency was determined by
agarose gel electrophoresis, immunofluorescence, and BCA
assay (see ESI†).
Evaluation of doxorubicin conjugation of Ab-DOX-NPs
DOX loading capacity (LC) and DOX conjugation efficiency
(CE; %) were calculated using the formulas described pre-
viously. The release profile of doxorubicin was analyzed by
high-performance liquid chromatography (HPLC) (see ESI†).
Cell culture
The CIC cell bank provided cell lines at the University of
Granada. The non-small cell lung cancer cell line H520 was
cultured in RPMI; A549, MCF-7, immortalized MEF and 143B
cell lines (lung cancer, breast cancer, mouse embryonic fibro-
blasts, and osteosarcoma, respectively) were cultured in
DMEM, supplemented with 10% (vol/vol), FBS, 1%
L-glutamine and 1% penicillin/streptomycin. Miguel Martin’s
laboratory kindly provided ρ0206 cells. ρ0206 cells were cul-
tured in similar media supplemented with 2% pyruvate
(GIBCO) and 50 μg mL−1 of uridine (SIGMA). Cells were main-
tained at 37 °C, 5% CO2, and 95% relative humidity, and were
regularly tested negative for mycoplasma infection.
Cellular nanofection by flow cytometry and confocal
microscopy
After incubation with NPs, the medium was aspirated, and the
cells were washed with 1× PBS and separated with trypsin-
EDTA at 37 °C for 5 min. Then, each sample was fixed in 2%
paraformaldehyde (PFA) at room temperature for 10 min and
protected from light. Samples were analyzed by flow cytometry
and confocal microscopy. Each experiment was performed in
duplicate by ratio and time of incubation and repeated at least
three times. The study of the nanofection of Ab-NPs and
control NPs was carried out using different cell : NP ratios at
the established incubation times. The dot plots and the cyto-
metry statistics were obtained using the FlowJo software. The
analysis of confocal microscopy images was subsequently
carried out with the ZEN 2012 program Blue Edition or ImageJ
version 1.49b (open-source software).
Cellular nanofection in coculture
H520 cells were identified by staining with CellTracker
(0.5 µM) for 45 min, according to the manufacturer’s protocol.
Stained H520 cells were washed twice. Then, A549 and stained
H520 cells were seeded in different proportions getting a total
of 105 cells per well: 10% : 90%; 25% : 75%; 50% : 50%; and
75% : 25%. Eighteen hours after seeding, EGFR-F-NPs (7A-1) or
EGFR-DOX-NPs (11-1) were added to each well at a concen-
tration of 5000 NPs per cell and incubated for 1.5 h.
Cell viability
The cellular cytotoxicity of NPs was evaluated using the resa-
zurin assay protocol.
Determination of DNA damage in cancer cells by
immunostaining of phospho-H2A·X foci
A549 and H520 cells were cultured on coverslips in 24-well
plates. Cells were incubated with 5000 EGFR-DOX-NPs (11-1)
per cell. After 24 h of incubation, the cells were fixed with 4%
PFA, washed, and incubated with primary antiphospho-H2A·X
antibodies in blocking buffer at +4 °C overnight. The next
day, cells were stained with secondary Alexa Fluor 488 conju-
gated antibodies for 1 h at room temperature. After washing
with PBS, the preparations were mounted with a mounting
medium including antifade and DAPI (Invitrogen).36 For
automatic H2A·X foci counting, ImageJ® analysis was
performed.
Statistical analysis
The data are presented as the mean ± the standard deviation.
The sample size (n) indicated the experimental repeats of a
single representative experiment and was set at 3 unless other-
wise specified. The results of the experiments were validated
by independent repetitions. Graph plotting and statistical
difference calculation were performed using GraphPad Prism
6.0 (Graphpad Software Inc.). Statistical significance was deter-
mined using the Student’s t-test in paired groups of samples
with a known median. A p-value of ≤0.05 was considered
significant.
Conclusions
An innovative and versatile approach for active targeted deliv-
ery based on the use of antibody-decorated nanoparticles has
been presented. For this proof of concept, the targeted delivery
in EGFR- and CD147-overexpressing cancer cells has been eval-
uated. NPs targeting EGFR or CD147 and decorated with either
fluorophores for tracking (EGFR-F-NPs (7A-1)), (EGFR-Cy5-NPs
(7B-1), and CD147-Cy5-NPs (7B-2) or with a drug for assessing
drug efficacy (EGFR-DOX-NPs (11-1) and CD147-DOX-NPs (11-
2)) were prepared and characterized. In vitro validation was
successfully achieved using several cancer cell lines with
different expression levels for the specific membrane recep-
tors. Remarkably, to our knowledge, this is the first nano-
carrier that has demonstrated a great selectivity in the cocul-
turing assay at short incubation times, with a clear ability to
efficiently discriminate between cell lines based on their
surface marker expression levels.
In conclusion, this manuscript describes procedures and
protocols that can be used to develop any combination of
robust nanoparticles conjugated to other antibodies and bio-
active molecules of interest. Therefore, we believe we are
offering an alternative therapeutic tool that can be potentially
used in personalized medicine.
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